Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead?
Should you forget Eli Lilly and buy this magnificent biotech instead? Let's find out.
Wolfe sees attractive Eli Lilly opportunity on price drop, starts at Outperform
Wolfe Research initiated coverage of Eli Lilly (LLY) with an Outperform rating and $1,000 price target The company has lost over $100B in ...
Lilly sues US agency over blocking of drug-rebate program
Lilly follows fellow drugmaker Johnson & Johnson (NYSE: JNJ ), who sued the Health and Human Services Department on Tuesday, ...
Investor's Business Daily on MSN18h
Stock Market Today: Chevron Breaks Out, But Biotechs Struggle As Eli Lilly Looks Like Short-Sale Play; Will American Airlines Break Out? (Live Coverage)
Investors continued to see multiple shades of light red as biotechs continued to struggle in the wake of the postelection ...
24/7 Wall St23h
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...
Moderna, Lily, Novavax, and Pfizer stocks fall after Trump nominates RFK Jr. as health secretary
Drug manufacturers saw their stock prices fall on Friday after vaccine skeptic Robert F. Kennedy Jr. was announced as Trump's ...